Key stats
About AdvisorShares Psychedelics ETF
Expense ratio
0.99%
Home page
Inception date
Sep 15, 2021
PSIL is an actively-managed portfolio of publicly-listed companies that derive at least 50% of their revenue or devote 50% of their assets to legal activities related to psychedelic medicines and their derivatives, excluding cannabis. It invests in stocks of US and foreign mid-, small-, and micro-cap firms and in swaps that provide the same exposure. PSIL aims to concentrate at least 25% of its investments in the Pharmaceuticals, Biotechnology & Life Sciences industry group. The fund adviser uses outside analyst ratings and stock selection rating tools to select companies that dominate their respective industries or are in unique positions for growth and expansion. Additionally, the fund has the ability to engage in stock lending, up to 33.3% of the portfolio, in order to increase income to the issuer.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region